Skip to main content
SpringerLink
Log in

GOBLET-Studie (AIO-KRK-0320)

Kombinationstherapien aus onkolytischem Virus (Pelareorep) und PD-L1-Inhibitor (Atezolizumab) mit oder ohne Chemotherapie bei fortgeschrittenen/metastasierten gastrointestinalen Tumoren: eine Phase I/II-Studie

The GOBLET study (AIO-KRK-0320)

Combination therapy with oncolytic virus (pelareorep) and PD-L1 inhibitor (atezolizumab) with or without chemotherapy in advanced/metastasized gastrointestinal tumors: a phase I/II study

  • Sektion B - Klinische Studien
  • Published:
Forum Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461–2471

    Article  CAS  Google Scholar 

  2. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y (2019) Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(11):1506–1517

    Article  CAS  Google Scholar 

  3. Andre T, Shiu K‑K, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith DM, Garcia-Carbonero R, Benavides M, Gibbs P, Fouchardiere CDL, Rivera F, Elez E, Bendell JC, Le DT, Yoshino T, Yang P, Farooqui MZH, Marinello P, Diaz LA (2020) Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study. J Clin Oncol 38(18_suppl):LBA4

    Article  Google Scholar 

  4. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773–779

    Article  CAS  Google Scholar 

  5. Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18(3):197–218

    Article  CAS  Google Scholar 

  6. Gujar S, Pol JG, Kim Y, Lee PW, Kroemer G (2018) Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies. Trends Immunol 39(3):209–221

    Article  CAS  Google Scholar 

  7. Samson A, Bentham MJ, Scott K, Nuovo G, Bloy A, Appleton E, Adair RA, Dave R, Peckham-Cooper A, Toogood G, Nagamori S, Coffey M, Vile R, Harrington K, Selby P, Errington-Mais F, Melcher A, Griffin S (2018) Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut 67(3):562–573

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Onkologie, Hämatologie, Palliativmedizin und Rheumatologie, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Paul-Ehrlich-Straße 1, 22763, Hamburg, Deutschland

    Maike Collienne &  Dirk Arnold

Authors
  1. Maike Collienne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Arnold.

Ethics declarations

Interessenkonflikt

M. Collienne und D. Arnold geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Collienne, M., Arnold, D. GOBLET-Studie (AIO-KRK-0320). Forum 36, 74–75 (2021). https://doi.org/10.1007/s12312-020-00892-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-020-00892-y

Search

Navigation